Spermosens

Spermosens AB (publ) to Host Live Q&A Webcast on 27 August 2026

Spermosens AB (publ) INTERIM REPORT APRIL – JUNE 2026

Notice of Extraordinary General Meeting in Spermosens AB (publ)

The shareholders of Spermosens AB (publ), reg. no. 559179-0380, are hereby invited to attend the Extraordinary General Meeting on Tuesday, 1 September 2026 at 10:00 a.m. at Medicon Village (The Spark), Scheeletorget 1, Lund, Sweden.

Kallelse till extra bolagsstämma i Spermosens AB (publ)

Aktieägarna i Spermosens AB, org. nr. 559179-0380, kallas härmed till extra bolagsstämma tisdagen den 1 september 2026 kl. 10.00 på Medicon Village (The Spark), Scheeletorget 1, i Lund.

Spermosens raises approx. SEK 4.85m in directed issue and calls EGM

The Board of Directors of Spermosens AB (publ) ("Spermosens" or the "Company") has today, pursuant to the authorisation granted by the Annual General Meeting held on 18 June 2026, resolved on a directed issue of approximately SEK 4.65 million through the issuance of up to 560,240,958 units, each consisting of one (1) share and one (1) warrant of series 2026/2029 issued free of charge (the "First Directed Issue"). The subscription price amounts to SEK 0.0083 per unit, corresponding to SEK 0.0083 per share, representing a discount of approximately fifteen (15) per cent compared with the volume-weighted average price (VWAP) of the Company's share during the ten (10) trading days immediately following the Company's call of capital under the Capital Facility.   The Board of Directors has furthermore resolved to convene an Extraordinary General Meeting to resolve on a separate directed issue of approximately SEK 0.2 million through the issuance of up to 24,096,384 units on the same terms and conditions, to Chairman of the Board Ulrik Spork and Duvold Holding ApS (the "Second Directed Issue" and, together with the First Directed Issue, the "Directed Issues"). Through the Directed Issues, the Company will receive gross proceeds of approximately SEK 4.85 million before transaction costs of approximately SEK 0.2 million. The Directed Issues are carried out pursuant to the Capital Facility announced by the Company on 7 May 2026 and approved by the Annual General Meeting held on 18 June 2026.

Spermosens calls SEK 4.85 million under previously announced Capital Facility

Spermosens AB (publ) ("Spermosens" or the "Company") hereby announces that the Board of Directors has today resolved to call capital under the capital facility of SEK 4.85 million that was announced on 7 May 2026 and subsequently approved by the Annual General Meeting on 18 June 2026. In accordance with the terms of the Capital Facility, the full available amount of SEK 4.85 million has been called. The capital will be contributed to the Company through the issuance of units to the investors participating in the Capital Facility.

Spermosens provides an update on the Generation 3 clinical study

Spermosens AB (publ) (“Spermosens” or the “Company”) provides an update on the ongoing clinical study of JUNO-Checked Generation 3 at the Reproductive Medicine Centre (RMC) in Malmö. Recruitment is progressing ahead of plan, with 43 patients included to date. The Company’s ambition remains, as previously communicated, to complete the study during 2026.

Bulletin from Annual General Meeting in Spermosens AB (publ)

Spermosens publishes annual report for the financial year 2025

Spermosens publicerar årsredovisning för räkenskapsåret 2025

NOTICE OF ANNUAL GENERAL MEETING 2026 IN SPERMOSENS AB (publ)

KALLELSE TILL ÅRSSTÄMMA 2026 I SPERMOSENS AB (publ)